Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has been given a $22.00 target price by investment analysts at Canaccord Genuity in a report released on Tuesday, August 8th. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s target price suggests a potential upside of 51.41% from the stock’s current price.
Other equities analysts have also issued reports about the company. BidaskClub raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Zacks Investment Research lowered Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. ValuEngine raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Cantor Fitzgerald set a $28.00 target price on Aquinox Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, May 9th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $22.25.
Aquinox Pharmaceuticals (AQXP) opened at 14.53 on Tuesday. The company’s market capitalization is $340.93 million. The firm has a 50-day moving average price of $14.42 and a 200-day moving average price of $15.32. Aquinox Pharmaceuticals has a 1-year low of $9.00 and a 1-year high of $19.97.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, hitting the consensus estimate of ($0.59). On average, analysts forecast that Aquinox Pharmaceuticals will post ($2.15) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.com-unik.info/2017/08/19/aquinox-pharmaceuticals-inc-nasdaqaqxp-pt-set-at-22-00-by-canaccord-genuity-updated.html.
In other Aquinox Pharmaceuticals news, insider David Main sold 15,625 shares of the stock in a transaction on Monday, June 5th. The stock was sold at an average price of $13.26, for a total transaction of $207,187.50. Following the completion of the transaction, the insider now directly owns 77,530 shares of the company’s stock, valued at $1,028,047.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.70% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in AQXP. Nexthera Capital LP purchased a new position in shares of Aquinox Pharmaceuticals during the second quarter valued at $1,276,000. Vanguard Group Inc. raised its position in shares of Aquinox Pharmaceuticals by 6.6% in the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after buying an additional 17,455 shares during the period. Northern Trust Corp raised its position in shares of Aquinox Pharmaceuticals by 3.3% in the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock valued at $1,171,000 after buying an additional 2,691 shares during the period. Sphera Funds Management LTD. purchased a new position in shares of Aquinox Pharmaceuticals during the second quarter valued at $874,000. Finally, Archon Partners LLC raised its position in shares of Aquinox Pharmaceuticals by 44.0% in the second quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock valued at $253,000 after buying an additional 5,500 shares during the period. 98.20% of the stock is owned by institutional investors and hedge funds.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
What are top analysts saying about Aquinox Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aquinox Pharmaceuticals Inc. and related companies.